



European Agency Approves Ventavis for Primary Pulmonary Hypertension

BERLIN, Sept. 22 /PRNewswire-FirstCall/ -- Schering AG, Germany (NYSE: SHR; FSE: SCH) announced today that the European Commission in a Centralized Procedure approved Schering's new drug Ventavis(R) for marketing in all EU countries. Ventavis(R) is an inhalation treatment for patients with primary pulmonary hypertension. It is the only prostacyclin product that targets the pulmonary vessels more directly by inhalation.

"Ventavis(R) improves the therapy for patients affected by severe symptoms and heart failure. It is a new, convenient treatment option for patients suffering from a life threatening disease," said Dr. Hubertus Erlen, CEO and Chairman of the Executive Board of Schering AG. "We will offer Ventavis(R) as soon as possible to doctors and patients in the EU countries."

Schering plans to start marketing Ventavis(R) in the first EU countries in 2003 and to roll-out the product in Europe fully by 2004. Ventavis(R) was designated as an orphan medicinal product in December 2000 and will fall under orphan drug protection until 2013.

Additional information

In May 2003, Schering received the positive opinion from the Committee of Proprietary Medicinal Products (CPMP). The CPMP is the scientific committee for human medicinal products of the European Agency for the Evaluation of Medicinal Products (EMEA) and its positive opinion a prerequisite of the EU decision.

The active substance of Ventavis(R) is iloprost, a synthetic prostacyclin analogue. The pharmacological effects after inhalation of Ventavis(R) are direct vasodilatation of the pulmonary arterial bed with consecutive significant improvement of pulmonary artery pressure, pulmonary vascular resistance and cardiac output as well as mixed venous oxygen saturation.

The benefits of Ventavis(R) include improvements in exercise capacity and symptoms. A randomized, double-blind, multi-center, placebo-controlled phase III trial has been conducted in 203 adult patients with stable pulmonary hypertension. Inhaled iloprost (or placebo) was added to patients' current therapy, which could include a combination of anticoagulants, vasodilators (e.g. calcium channel blockers), diuretics, oxygen, and digitalis, but not prostacyclin or its analogues.



More Headlines

What to Expect in Senate's Health Care Bill

GOP leaders pursue moderate votes

White House Task Force Echoes Pharma Proposals

Industry influences working group's deliberations, report contends

FDA Readying Regulatory Plan for Digital Health Devices

Novel "post-market approach" expected this fall

FDA Approves Darzalex in Combination with Pomalidomide and Dexamethasone for Patients With Multiple Myeloma

New approval augments previous myeloma indications

FDA Expands Dysport Label to Include Lower-Limb Spasticity in Adults

Botulinum toxin product carries boxed warning

State Attorneys General Probe Opioid Drug Companies

Officials suspect marketing scheme to promote chronic opioid use

Cleveland Clinic Jumps Into Insurance Business

Move blurs line between payer and provider

C-Suite Survey: Health Care Leaders Use Generics, Tighter Formularies, Physician Education to Control Drug Spending

Most respondents anticipate increased drug expenses over the next five years

FDA Approves EpiPen Rival

Symjepi provides two single-dose syringes of epinephrine

STAY IN TOUCH! NEWSLETTERS AVAILABLE:

- P&T and drug management daily news
- P&T table of contents (monthly)

USEFUL LINKS

- About P&T
- 2017 Media kit
- 2017 Space and materials due dates
- Terms and conditions for using this site
- Masthead

INDUSTRY ANNOUNCEMENTS

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

Share buy-back week 22/2017

Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label

Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting



- Editorial board
- Subscribe
- Renew your subscription
- Update your subscription
- Subscription customer service
- BPA statement
- RSS feed
- Contact webmaster

CONTACT US

Editorial: J. Stephen McIver, Editor

Advertising:

Maureen Dwyer Liberti, Vice President, Group Publisher **Production:** Dawn Flook, Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Webmaster: Webmaster

From the PharmD Corner

Beyond the pills: Accountable Health Communities highlight social comorbidities that affect our health

Mimi Chen, PharmD



VALNEVA to Present at Jefferies 2017 Global Healthcare Conference in New York

Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London

Lundbeck obtains rights to breakthrough research in Alzheimer's disease

Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China

More from Globe NewsWire

CURRENT ISSUE OF P&T

June 2017





NEWS CENTER

Approvals, Launches, & New Indications

Pipeline Plus

Research News

Industry Trends

Safety Issues

Agency Actions

Health Care Reform

Guidelines

Clinical Trials

Drug Forecast

NAVIGATION

- Popular content
- Search
- Site map
- Managed Care magazine

USER LOGIN

Username *

Password *



Terms and Conditions for Using this Site $\ensuremath{\texttt{@}}$ 2017 Medi
Media, an ICON Plc company. All Rights Reserved.

